Samfara completes acquisition of Chr. Olesen Synthesis, Danish API maker
Samfara, a European life sciences investor, says it has completed the acquisition of Chr. Olesen Synthesis, a Copenhagen-area producer of active pharmaceutical ingredients (APIs) and intermediates, with a focus on controlled substances used in opioid use disorder and attention-deficit/hyperactivity disorder therapies. The deal, financed by a mix of European and North American investors, marks Samfara’s first investment and involves other investors and funds; terms were not disclosed. Chr. Olesen Synthesis has operated since 2015 and supplies pharmaceutical companies across Europe, North America and the Middle East. This explainer breaks down what happened, who could be affected, and what to expect next.
What changed in ownership and why it matters
The buyer, Samfara, announced it completed the acquisition of Chr. Olesen Synthesis from the company and funds managed by Signet Healthcare Partners. The transaction is described as a first investment for Samfara, backed by a syndicate of institutional investors and family offices in Europe and North America. Financial terms were not disclosed. Chr. Olesen Synthesis continues to operate as a producer of APIs and advanced intermediates, especially for controlled substances used in opioid use disorder (such as buprenorphine) and ADHD (such as lisdexamfetamine). The plant is cGMP-certified, meaning it adheres to current good manufacturing practices required for pharmaceutical manufacturing. Expect continuity in the supplier's operations, with strategic backing from Samfara as it expands its customer reach.What to watch next:any announced plans for capacity expansion, product lines, or changes in supply to European and North American pharma customers.
Key facts about the transaction and the company
- The acquisition is Samfara’s first investment. — worth weighing when comparing Samfara completes acquisition Chr. options in Manama.
- Chr. Olesen Synthesis specializes in controlled substances APIs and related intermediates.
- Products include APIs used to treat opioid use disorder (buprenorphine) and ADHD (lisdexamfetamine).
- The plant is cGMP-certified and has been producing commercially since 2015.
- Operations serve Europe, North America and the Middle East.
- Financial terms were not disclosed. — worth weighing when comparing Samfara completes acquisition Chr. options in Manama.
Who could be affected
Pharma customers in Europe, North America and the Middle East that rely on Chr. Olesen Synthesis for controlled-substance APIs may experience continuity in supply due to the new backing. Investors and employees at Chr. Olesen Synthesis could see strategic changes aligned with Samfara’s portfolio goals. Patients and health systems relying on medications containing these APIs are not directly affected by the change in ownership unless there is a disruption in supply or changes to product offerings.
Practical next steps for readers and stakeholders
- Pharma companies: monitor supplier communications for any changes in lead times or batch availability.
- Investors and analysts: note this as Samfara’s first investment and watch for details on strategy and additional funding rounds.
- Regulators and partners: expect ongoing compliance with cGMP standards; review any notices related to controlled substances in supply chains.
Limits and questions
Public disclosures from the firms do not include financial terms, which limits assessment of economic impact. The impact on pricing, capacity, or product scope will depend on future filings or company disclosures. For now, details beyond the basic facts of completion and backers are sparse.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- adnkronos.com — evidence source reviewed for this article.
- cagliarilivemagazine.it — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.